Clinical Dilemmas in Primary Liver Cancer

Clinical Dilemmas in Liver Cancer follows the successful format of the other books in the Clinical Dilemmas series, with each chapter focused on a specific dilemma, or issue facing doctors in their day-to-day job, and providing them with practical clinical information and help to better assessment and treat their patients in this case patients suffering from liver cancer, the third commonest cancer in terms of mortality worldwide. Chapters feature up-to-date information on the basic mechanisms, epidemiological risk factors, screening and surveillance strategies, diagnosis and treatment. It is an extremely practical and clinically-orientated book, and as most patients around the world present with advanced disease, a main focus is on the most recent advances allowing early diagnosis and use of locoregional and systemic therapy, surgery, transplantation and combination therapies. Each chapter is authored by an international expert in the relevant area.

Clinical Dilemmas in Liver Cancer follows the successfulformat of the other books in the Clinical Dilemmas series, witheach chapter focused on a specific dilemma, or issue facing doctorsin their day-to-day job, and providing them with practical clinicalinformation and help to better assessment and treat their patients in this case patients suffering from liver cancer, thethird commonest cancer in terms of mortality worldwide.Chapters feature up-to-date information on the basic mechanismsepidemiological risk factors, screening and surveillancestrategies, diagnosis and treatment. It is an extremely practicaland clinically-orientated book, and as most patients around theworld present with advanced disease, a main focus is on themost recent advances allowing early diagnosis and use oflocoregional and systemic therapy, surgery, transplantation andcombination therapies. Each chapter is authored by an internationalexpert in the relevant area.

List of Contributors, viiPreface, xPart 1: Learning from a Worldwide Perspective1 Are patterns and prevalence changing?, 3Hashem B. El-Serag2 Why is the tumour different in Africa?, 11Nimzing G. Ladep3 Control by vaccination: Asian and Taiwan experience, 18Jia-Horng Kao4 The view from the United Kingdom, 24Shahid A. Khan, Mireille B. Toledano, Abigail Zabron, Mehtan Ahmed, and Simon D. Taylor-Robinson5 The view from the United States, 29Hitoshi Maruyama and Arun J. Sanyal6 New challenges of the NAFLD and HIV epidemics, 35Quentin M. Anstee and Janice MainPart 2: Influence of Tumour Characteristics7 Controversies in pathology, 45Tania Roskams8 Not to forget the unusual tumour, 53Bernard C. Portmann9 What can be learned from molecular diagnostic techniques and genetic signatures?, 60Tariq Moatter and Saeed HamidPart 3: Complexities of Patient Assessment and Scoring Systems10 Looking after the liver as well as the tumour, 67Roger Williams11 Comparative performances of staging systems for hepatocellular cancer: early HCC considerations, 75Peter D. Peng and Timothy M. Pawlik12 Rival scoring systems: do they offer more?, 81Angelo Sangiovanni and Massimo Colombo13 Is it possible to detect early lesions effectively?, 91Ryota Masuzaki and Masao Omata14 What is the value of country-based surveillance programmes?, 97Peter OttPart 4: Choice of Radiological Diagnostic Technique15 Computed tomography or magnetic resonance imaging for the diagnosis of hepatocellular carcinoma, 107Wladyslaw Gedroyc16 Is Microbubble ultrasound useful?, 114Adrian Lim17 Value of PET scanning, 118Tara D. Barwick, Imene Zerizer, and Adil Al-NahhasPart 5: Can Treatment be Tailored to the Patient?18 Who could benefit from chemoembolisation?, 127Gisele N'Kontchou, Olivier Seror, and Michel Beaugrand19 Are drug-eluting beads worth using?, 136Christopher N. Hacking and Pradesh Kumar20 What is the future of image-guided radiofrequency ablation for hepatocellular carcinoma?, 142Riccardo Lencioni21 Alternative ablation techniques for hepatocellular carcinoma, 149John Karani22 Justification for sorafenib and chemotherapy, 154Philip J. Johnson23 When to consider surgery?, 160Emmanuel Melloul, Mickael Lesurtel, and Pierre-Alain Clavien24 Transplant considerations, 168Myron SchwartzPart 6: What Does the Future Hold?25 Dipstick markers for diagnosis: feasible or not?, 179Mohamed I.F. Shariff and Simon D. Taylor-Robinson26 Targeted gene therapy for hepatocellular carcinoma: a reality?, 184Christopher Binny, Marco Della Peruta, and Amit C. Nathwani27 Is immune modulation a possibility?, 191Tim F. Greten and Firouzeh Korangy28 Systemic therapy for hepatocellular carcinoma: future directions, 199Daniel H. Palmer, Matthew E. CrampIndex, 212Colour plate section can be found facing page 86